Bone Strength, Hormonal Support, and the Icariin Advantage

How icariin, the active compound in the traditional Chinese herb epimedium, supports bone density, hormonal balance, and cardiovascular health

Epimedium is a leafy herb used in traditional Chinese medicine for over a thousand years, most commonly known in the West as "horny goat weed." Its active compound, icariin, is a flavonoid that influences bone-building cells, modulates hormonal pathways, and inhibits the same enzyme targeted by pharmaceutical drugs for cardiovascular and sexual health. Clinical research shows it can meaningfully slow bone loss in postmenopausal women without the risks of estrogen therapy [1][2]. This is one of the few traditional herbs with human randomized controlled trial data supporting its primary traditional use.

How Epimedium Works

Icariin and the Active Metabolites

Epimedium species — particularly Epimedium brevicornum, E. sagittatum, and E. grandiflorum — contain a family of prenylated flavonoids, with icariin being the best-studied. When taken orally, icariin is not well-absorbed intact; gut bacteria and intestinal enzymes convert it into smaller, more bioavailable metabolites: primarily icaritin and desmethylicaritin [2]. These metabolites are what actually circulate in the bloodstream and interact with receptors. This biotransformation means the quality of your gut microbiome influences how much benefit you get from epimedium supplementation.

Bone Health: The Primary Evidence

Bone is constantly being remodeled — old bone is broken down by cells called osteoclasts, and new bone is laid down by osteoblasts. In postmenopausal women, falling estrogen levels tip this balance toward bone resorption, causing bone mineral density to fall and osteoporosis risk to rise. Icariin and its metabolites work on both sides of this equation:

Osteoblast activation: Icariin promotes the differentiation of bone marrow stem cells into osteoblasts via multiple pathways, including the Wnt/beta-catenin signaling cascade and bone morphogenetic protein (BMP) signaling [4].
Osteoclast suppression: Icaritin downregulates TRAF6, an adapter protein critical for osteoclast survival and activity. The 2021 clinical trial found a trend toward reduced TRAF6 expression in circulating monocytes after 6 weeks of supplementation [2].
Phytoestrogenic effects: Icariin weakly binds estrogen receptor alpha (ERα), mimicking some bone-protective effects of estrogen without strongly stimulating breast or uterine tissue — a key advantage over hormone replacement therapy.

The landmark 2007 clinical trial enrolled 100 late postmenopausal women and followed them for 24 months [1]. Those who received icariin-containing epimedium extract (60 mg icariin per day plus phytoestrogen cofactors) maintained or slightly increased bone mineral density at the femoral neck and lumbar spine, while the placebo group lost bone at both sites. The bone resorption marker deoxypyrdinoline fell 43% in the treatment group at 12 months. Crucially, serum estradiol levels and endometrial thickness did not change — confirming the herb acted on bone without the hormone-stimulating effects that make estrogen therapy risky for some women.

Cardiovascular and Blood Flow Effects

Icariin inhibits phosphodiesterase type 5 (PDE5), the same enzyme blocked by sildenafil (Viagra) and tadalafil (Cialis). PDE5 degrades cyclic GMP (cGMP), a messenger molecule that relaxes smooth muscle in blood vessel walls. By inhibiting PDE5, icariin allows cGMP to accumulate, promoting vasodilation and improved blood flow [5]. The potency is substantially lower than pharmaceutical PDE5 inhibitors at standard supplemental doses, but the mechanism is real and well-characterized. This effect supports circulation broadly — not just reproductive tissue — and may contribute to modest blood pressure reduction.

Neuroprotection

Animal research suggests icariin protects neurons through multiple mechanisms: preserving mitochondrial function, reducing amyloid-beta plaque deposition, activating BDNF/TrkB neuroprotective signaling, and reducing neuroinflammation [6]. These findings come from Alzheimer's model studies in mice and rats, not human trials — so their translation to humans remains speculative. That said, the mechanistic consistency with icariin's known anti-inflammatory and antioxidant actions makes this an active area of research interest.

Anti-Inflammatory Action

Icariin activates the Nrf2/HO-1 pathway — the body's master antioxidant defense program — while simultaneously suppressing NF-kB, the central regulator of pro-inflammatory cytokines [7]. This dual action is similar to quercetin, sulforaphane, and other polyphenol compounds. At a cellular level, it means icariin can dampen inflammation from multiple angles without simply blocking a single inflammatory mediator.

Dosage and Practical Guidance

Bone health: Clinical research used 60 mg/day of icariin (within an epimedium extract) over 24 months. This requires a standardized extract — raw herb powder provides unpredictable amounts of icariin.
General supplementation: Many products standardize to 10–40% icariin; 500 mg of a 20% standardized extract delivers 100 mg icariin daily.
Absorption note: Icariin is better absorbed with food, and the gut microbiome matters for conversion to active metabolites.
Safety: Both clinical trials found no liver, kidney, or blood toxicity at tested doses [1][2]. Epimedium is not recommended during pregnancy. At high doses, some sources report dry mouth or nosebleeds.
Drug interactions: Due to PDE5 inhibition, avoid combining with pharmaceutical PDE5 inhibitors (sildenafil, tadalafil) or nitrate medications.

For related bone-protective support, see our Vitamin K2 page and Strontium page. For other hormonal herbs, see Tongkat Ali and Shatavari.

Evidence Review

Human Clinical Evidence: Two Randomized Controlled Trials

The most significant human trial is Zhang, Qin, and Shi (PMID 17419678), published in the Journal of Bone and Mineral Research in 2007. This was a 24-month double-blind, placebo-controlled trial in 100 healthy late postmenopausal Chinese women (mean age approximately 64, 15+ years post-menopause). Participants received either an epimedium-derived phytoestrogen preparation (60 mg icariin + 15 mg daidzein + 3 mg genistein daily, plus 300 mg calcium) or calcium-only placebo. Of 100 enrolled, 85 completed the full 24 months.

Results were statistically significant at both skeletal sites:

Lumbar spine BMD: +1.3% in the treatment group vs. -2.4% in placebo at 24 months (between-group difference p = 0.006)
Femoral neck BMD: +1.6% vs. -1.8% (p = 0.008)
Bone resorption marker (deoxypyrdinoline): -43% at 12 months and -39% at 24 months in treatment group; slight increase in placebo group

Importantly, serum estradiol levels did not change significantly from baseline in either group, and endometrial thickness by ultrasound was unchanged — ruling out systemic estrogenic effects on reproductive tissue. This safety profile is a crucial distinction from estrogen therapy. The formulation included daidzein and genistein alongside icariin, so the observed effects cannot be attributed to icariin alone — though the preponderance of mechanistic evidence points to icariin as the primary active ingredient.

The 2021 trial (PMID 34352588), published in Phytomedicine by Yong et al. at the National University of Singapore, enrolled 58 postmenopausal women (mean age 57.9, BMI 24.0) in a 6-week placebo-controlled study using 740 mg/day of an epimedium extract. This trial focused primarily on safety and pharmacokinetics. Key outcomes:

Bone-specific alkaline phosphatase (BSAP): Significantly higher in treatment vs. placebo (p < 0.05), indicating increased bone formation activity
TRAF6 expression: Trend toward reduction in peripheral blood monocytes (p = 0.068), suggesting suppression of osteoclast signaling
Safety: No clinically significant changes in liver enzymes, full blood count, renal markers, or lipid panels. No serious adverse events.
Pharmacokinetics: Icariin itself was largely undetectable in plasma; primary metabolites were desmethylicaritin (Cmax 60.9 nM) and icaritin, confirming that gut conversion of icariin drives bioavailability.

Six weeks is too short to detect BMD changes, but the pharmacokinetic and biomarker data provide crucial mechanistic confirmation of the longer-term trial.

Animal Meta-Analysis: Comparable Efficacy to Estrogen in Bone

Xu et al. (PMID 27648597), published in Menopause in 2016, conducted a meta-analysis of 7 randomized animal studies using ovariectomized (surgically menopausal) rats — the standard preclinical model for postmenopausal osteoporosis. Key findings from 169 animals:

Icariin significantly improved bone mineral density vs. untreated controls (WMD 0.02, 95% CI 0.01–0.02)
No significant difference between icariin and estrogen treatment across 6 studies (WMD 0.00, 95% CI -0.00 to 0.01)

The equivalence to estrogen in bone-protective efficacy at this preclinical level, combined with icariin's lack of estrogenic effects on other tissues, is the mechanistic basis for its use as a safer alternative to HRT for bone health. Animal models don't translate directly to humans, but the pattern is consistent with the human trial data.

Mechanistic Review: Bone Metabolism Pathways

Wang et al. (PMID 29110063) published a comprehensive mechanism review in Osteoporosis International (2018) synthesizing the cellular biology. Icariin promotes osteogenesis via:

BMP/Smad pathway: Icariin increases BMP-2 expression and downstream Smad1/5/8 phosphorylation, driving mesenchymal stem cell commitment toward the osteoblast lineage
Wnt/beta-catenin: Icariin upregulates Wnt ligands and inhibits Wnt antagonists (Dkk-1, sclerostin), enhancing bone matrix synthesis
Runx2 transcription factor: The master regulator of osteoblast differentiation is activated by icariin at the gene expression level
RANKL/OPG ratio: Icariin shifts the osteoclast-regulating RANKL/OPG balance toward OPG, reducing osteoclast recruitment and activity

The review notes icariin's superior potency over other flavonoids — including daidzein and genistein — in osteogenic assays, supporting its role as the primary active compound in epimedium.

Cardiovascular: PDE5 Inhibition Mechanism

Ning et al. (PMID 17169663), from UC San Francisco, were among the first to formally characterize icariin's PDE5 inhibitory activity. Icariin inhibited all three PDE5A isoforms with IC50 values of approximately 1.0 μM — substantially lower potency than sildenafil but mechanistically valid. In isolated human cavernous smooth muscle cells, icariin at 200 μM significantly elevated intracellular cGMP. The practical implication is that at standard supplemental doses, icariin likely produces mild PDE5 inhibition — enough to support blood vessel relaxation and circulation without the pronounced hemodynamic effects of pharmaceutical doses.

Neuroprotection: Alzheimer's Model Evidence

Chen et al. (PMID 26584824) studied icariin in triple-transgenic (3xTg-AD) Alzheimer's mice, which express human APP, presenilin-1, and tau mutations. Animals receiving icariin showed:

Significantly better spatial memory performance (Morris Water Maze escape latency and platform crossings)
Reduced amyloid-beta plaque density in cortex and hippocampus
Decreased BACE1 expression (the enzyme responsible for amyloid precursor protein cleavage)
Preserved mitochondrial enzyme function (COX IV, PDHE1alpha)
Maintained N-acetylaspartate (a neuronal viability marker) and ATP production

These are animal findings in a genetic model that doesn't perfectly replicate human Alzheimer's disease. No human clinical trials have been conducted on icariin for cognitive outcomes, and this area of research requires cautious interpretation.

Anti-Inflammatory: Dual-Pathway Modulation

El-Shitany and Eid (PMID 31670031) demonstrated in an acute carrageenan-induced inflammation model in rats that icariin (50 mg/kg) simultaneously activated the Nrf2/HO-1 antioxidant pathway (increasing superoxide dismutase, catalase, and reduced glutathione) while suppressing NF-kB and its downstream targets including COX-2, TNF-alpha, and IL-6. Dual modulation of both the antioxidant and pro-inflammatory arms of the cellular stress response is a characteristic of several plant polyphenols with confirmed clinical benefit.

Evidence Strength Assessment

The evidence for epimedium's bone-protective effects in postmenopausal women is moderate-to-strong for a botanical supplement — two human RCTs, a preclinical meta-analysis, a comprehensive mechanistic review, and internally consistent biology. The 24-month duration and dual skeletal-site significance of the 2007 trial are particularly credible. The cardiovascular (PDE5) and anti-inflammatory mechanisms are well-established in vitro; human clinical evidence for these effects is lacking. Neuroprotection remains preclinical. Overall, epimedium has the most robust evidence base in bone health, with plausible but unconfirmed additional benefits.

References

Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trialZhang G, Qin L, Shi Y. Journal of Bone and Mineral Research, 2007. PubMed 17419678 →
Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post-menopausal womenYong EL, Cheong WF, Huang Z, Win Pa Pa Thu, Cazenave-Gassiot A, Seng KY, Logan S. Phytomedicine, 2021. PubMed 34352588 →
Bone mass improved effect of icariin for postmenopausal osteoporosis in ovariectomy-induced rats: a meta-analysis and systematic reviewXu JH, Yao M, Ye J, Wang GD, Wang J, Cui XJ, Mo W. Menopause, 2016. PubMed 27648597 →
The effect of icariin on bone metabolism and its potential clinical applicationWang Z, Wang D, Yang D, Zhen W, Zhang J, Peng S. Osteoporosis International, 2018. PubMed 29110063 →
Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cellsNing H, Xin ZC, Lin G, Banie L, Lue TF, Lin CS. Urology, 2006. PubMed 17169663 →
Neuroprotective Effects of Icariin on Brain Metabolism, Mitochondrial Functions, and Cognition in Triple-Transgenic Alzheimer's Disease MiceChen YJ, Zheng HY, Huang XX, Han SX, Zhang DS, Ni JZ, He XY. CNS Neuroscience & Therapeutics, 2016. PubMed 26584824 →
Icariin modulates carrageenan-induced acute inflammation through HO-1/Nrf2 and NF-kB signaling pathwaysEl-Shitany NA, Eid BG. Biomedicine & Pharmacotherapy, 2019. PubMed 31670031 →